> top > projects > ASCO_abstracts > docs
ASCO_abstracts  

Documents (3,155) JSON TSV

source DB source ID text size updated at # proj. # Ann. updated_at
asco@alo33 161695 Background: Sertoli Leydig cell tumors SLCT of the ovary are rare, and usually present as progressive virilization in omen in their second to third decade of life. Less than 10 percent of patients 2.31 KB 2023-01-16 1 2023-01-16
asco@alo33 161696 Background: There are fe reports about patients prognosis depending on primary sites of cancer in palliative care settings. Methods: This study as conducted as a secondary analysis for a large prosp 2.29 KB 2023-01-16 1 2023-01-16
asco@alo33 161708 Background: The role of regional lymphadenectomy LA in omen ith stage I endometrial carcinoma EC is controversial. The objective of the study is to determine the prognostic impact of LA on survi 2.27 KB 2023-01-16 1 2023-01-16
asco@alo33 161712 Background: SCCBis a rare, aggressive form of breast cancer that is associated ith extremely poor outcomes Hare 2015 . In an effort to identify ne treatment options, e utilized comprehensive genomi 1.83 KB 2023-01-16 1 2023-01-16
asco@alo33 161736 Background: About 45 percent of oncologists report burnout BO despite high careerspecialty satisfaction CSSS . Little is knon about BO and CSSS among Physician Assistants PAs in oncology onc . 2.49 KB 2023-01-16 1 2023-01-16
asco@alo33 161747 Background: This multicenter phase II trial assessed the safety and efficacy of docetaxel plus 5-fluorouracil and cisplatin DCF induction chemotherapy IC and subsequent conversion surgery CS f 2.23 KB 2023-01-16 1 2023-01-16
asco@alo33 161764 Background: In an effort to decrease time to diagnosis andor treatment intervention in nely diagnosed veteran cancer patients, Hudson Valley administrators chose the disease case management team mod 2.14 KB 2023-01-16 1 2023-01-16
asco@alo33 161786 Background: Precision medicine and prediction of therapeutic response requires monitoring potential biomarkers before and after treatment. Liquid biopsies provide noninvasive prognostic markers such 2.26 KB 2023-01-16 1 2023-01-16
asco@alo33 161787 Background: Several risk factors for febrile neutropenia FN have been identified in previous studies eg, chemotherapy [chemo] dose intensity, advanced age, and comorbidities . The possible biolog 2.41 KB 2023-01-16 1 2023-01-16
asco@alo33 161798 Background: We aim to quantify the relationship beteen pretreatment comorbidity and survival outcomes for patients ith locally-advanced larynx cancer. Methods: We retrospectively revieed records of 2.38 KB 2023-01-16 1 2023-01-16